The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076
Expires: August 31, 2015
Estimated average burden
hours per
response: 4.00

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001454789			X Corporation
Name of Issuer			Limited Partnership
CATABASIS PHARMACEUT	ICALS INC		Limited Liability Company
Jurisdiction of Incorporation/	Organization		General Partnership
DELAWARE			
Year of Incorporation/Organia	zation		Business Trust
Over Five Years Ago			Other (Specify)
X Within Last Five Years (Specify Year) 2008		
Yet to Be Formed			
2. Principal Place of Busine	ess and Contact Information		
Name of Issuer			
CATABASIS PHARMACEUT	ICALS INC		
Street Address 1		Street Address	s 2
ONE KENDALL SQUARE		BLDG. 1400E, S	SUITE 14202
City	State/Province/Country	ZIP/PostalCode	le Phone Number of Issuer
CAMBRIDGE	MASSACHUSETTS	02139	617-349-1971
3. Related Persons			
Last Name	First Name		Middle Name
Milne	Jill		Widdle Hallie
Street Address 1	Street Address 2		
One Kendall Square	Bldg. 1400E, Suite		
City	State/Province/C		ZIP/PostalCode
Cambridge	MASSACHUSETT		02139
Relationship: X Executive 0	Officer X Director Promoter		
Clarification of Response (if I	Necessary):		
Last Name	First Name		Middle Name
Jirousek	Michael		
Street Address 1	Street Address 2		
One Kendall Square	Bldg. 1400E, Suite	e B14202	
City	State/Province/C	ountry	ZIP/PostalCode
Cambridge	MASSACHUSETT	ΓS	02139
Relationship: X Executive 0	Officer Director Promoter		
Clarification of Response (if N	Necessary):		
Last Name	First Name		Middle Name
Galakatos	Nicholas		
Street Address 1	Street Address 2		
One Kendall Square	Bldg. 1400E, Suite	e B14202	

City	State/Province/Country	ZIP/PostalCode	
Cambridge	MASSACHUSETTS	02139	
Relationship: Executive Office	er X Director Promoter		
Clarification of Response (if Nece	essary):		
Last Name	First Name	Middle Name	
Ross	Michael		
Street Address 1	Street Address 2		
One Kendall Square	Bldg. 1400E, Suite B14202		
City	State/Province/Country	ZIP/PostalCode	
Cambridge	MASSACHUSETTS	02139	
Relationship: Executive Office	er X Director Promoter		
Clarification of Response (if Nece	essary):		
Last Name	First Name	Middle Name	
Laufer	Ron		
Street Address 1	Street Address 2		
One Kendall Square	Bldg. 1400E, Suite B14202		
City	State/Province/Country	ZIP/PostalCode	
Cambridge	MASSACHUSETTS	02139	
Relationship: Executive Office	er X Director Promoter		
Clarification of Response (if Nece	essary):		
4. Industry Group			

Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	
Insurance		Technology
Investing	Hospitals & Physicians	Computers
Investment Banking	X Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes No	Comptension	
Other Banking & Financial Services	Construction	Tourism & Travel Services
	REITS & Finance	Other Travel
	Residential	Other
Business Services	Other Real Estate	
Energy		
Coal Mining		
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Va	alue Range
No Revenues	No Aggregate Net As	-
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	0,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00	00,000
\$25,000,001 -	\$50,000,001 - \$100,0	000,000
\$100,000,000 Over \$100,000,000	Over \$100,000,000	
X Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s) Cla		
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504 (b)(1)(i)	X Rule 506	
Rule 504 (b)(1)(ii)	Securities Act Sect	
Rule 504 (b)(1)(iii)	Investment Compar	ny Act Section 3(c)

Section	n 3(c)(1)	Section 3(c)(9)	
Section	n 3(c)(2)	Section 3(c)(10)	
Section	n 3(c)(3)	Section 3(c)(11)	
Section	n 3(c)(4)	Section 3(c)(12)	
	n 3(c)(5)	Section 3(c)(13)	
	n 3(c)(6)	Section 3(c)(14)	
	n 3(c)(7)		
Section	11 3(0)(7)		
7. Type of Filing			
New Notice Date of First Sale 2013-01-18 \square First Sale Yet \overline{X} Amendment	t to Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more than one year?	Yes X	No	
9. Type(s) of Securities Offered (select all that apply)			
X Equity		Pooled Investment Fund Interests	
Debt		Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or Calling Right to Acquire Security	Other	Other (describe)	
10. Business Combination Transaction			
Is this offering being made in connection with a business combinemerger, acquisition or exchange offer?	nation transa	action, such as a Yes X No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside investor \$0 USD	D		
12. Sales Compensation			
Recipient	Recipien	t CRD Number X None	
(Associated) Broker or Dealer X None	(Associa	ited) Broker or Dealer CRD Number X None	
Street Address 1		ddress 2	
		ovince/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Forei	gn/non-US	
13. Offering and Sales Amounts			
Total Offering Amount \$9,195,865 USD or Indefinite			
Total Amount Sold \$9,195,865 USD			
Total Remaining to be Sold \$0 USD or Indefinite			
Clarification of Response (if Necessary):			
14. Investors			
Select if securities in the offering have been or may be sold the enter the number of such non-accredited investors who alread			
Regardless of whether securities in the offering have been or investors, enter the total number of investors who already har	or may be so ave invested	Id to persons who do not qualify as accredited I in the offering:	14

Terms of Submission

file this notice.

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
CATABASIS PHARMACEUTICALS INC	/s/ Jill Milne	Jill Milne	Chief Executive Officer	2013-06-27

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.